These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1182 related articles for article (PubMed ID: 19382250)

  • 1. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.
    Yuen MF; Wong DK; Sablon E; Yuan HJ; Sum SM; Hui CK; Chan AO; Wang BC; Lai CL
    Antivir Ther; 2003 Dec; 8(6):531-4. PubMed ID: 14760886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
    Xu LJ; Pan C; Li QG; Chen RH; Zheng L; Zhang QY; Chen HC
    Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):180-3. PubMed ID: 20380793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus genotyping, core promoter, and precore/core mutations among Afghan patients infected with hepatitis B: a preliminary report.
    Amini-Bavil-Olyaee S; Alavian SM; Adeli A; Sarrami-Forooshani R; Sabahi F; Sabouri E; Tavangar HR; Azizi M; Mahboudi F
    J Med Virol; 2006 Mar; 78(3):358-64. PubMed ID: 16419114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-core/basal-core promoter and reverse transcriptase mutations in chronic HBV infected-patients.
    Xu L; Chen EQ; Lei J; Liu L; Zhou TY; Gao Z; Tang H
    Hepatogastroenterology; 2012; 59(113):212-5. PubMed ID: 22251541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
    Huang YH; Wu JC; Chang TT; Sheen IJ; Huo TI; Lee PC; Su CW; Lee SD
    J Viral Hepat; 2006 May; 13(5):336-42. PubMed ID: 16637865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
    Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
    J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
    Roque-Afonso AM; Férey MP; Mackiewicz V; Fki L; Dussaix E
    Antivir Ther; 2003 Dec; 8(6):627-34. PubMed ID: 14760897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YMDD mutations and genotypes of hepatitis B virus in northern China.
    Li D; Gu HX; Zhang SY; Zhong ZH; Zhuang M; Hattori T
    Jpn J Infect Dis; 2006 Feb; 59(1):42-5. PubMed ID: 16495633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.